Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;10(2):249-261.
doi: 10.1007/s40801-023-00354-6. Epub 2023 Apr 8.

A Retrospective Real-World Observational Study Assessing the Evolution of Bisacodyl Prescriptions in Patients with Constipation During Long-Term Treatment

Michel Bouchoucha  1 , Caroline Amand  2 , Beatrice Bois De Fer  2 , Robert Lange  3
Affiliations

A Retrospective Real-World Observational Study Assessing the Evolution of Bisacodyl Prescriptions in Patients with Constipation During Long-Term Treatment

Michel Bouchoucha et al. Drugs Real World Outcomes. 2023 Jun.

Abstract

Background: Potential habituation could be a safety concern associated with the long-term use of bisacodyl in patients with constipation.

Objective: In this study, we evaluated whether patients with constipation who require long-term treatment with bisacodyl will remain on a stable dose when treated for ≥ 28 days.

Methods: In this retrospective, population-based, observational cohort study, electronic medical record data of adult patients with constipation between January 1, 2011, and December 31, 2019, were collected from The Health Improvement Network French database. Total bisacodyl exposure during the long-term (≥ 28 days) and follow-up (12 months) periods was evaluated. The primary endpoint was the dose change status of bisacodyl during the follow-up period from the initial dose in the long-term cohort.

Results: Out of 5725 bisacodyl users in the database, 218 patients qualified to be part of the long-term cohort. A total of 166 (76.1%), 37 (17%), and 15 (6.9%) patients were initiated on bisacodyl at 5, 7.5, and 10 mg, respectively. During the follow-up, most (94%) of the patients remained on the same dose as initially prescribed for the first year. In contrast, only seven (3.2%) patients had their dose increased (from the initial prescribed dose of 5 mg), and the remaining six (2.8%) patients decreased their dose (four patients from the 7.5 mg group and two from the 10 mg group).

Conclusion: Bisacodyl can be prescribed at a stable dose for > 28 days as most patients remained on their initial prescribed dose during the follow-up period. No signs of habituation were observed in this real-world study.

PubMed Disclaimer

Conflict of interest statement

Michel Bouchoucha participated in a data safety monitoring board or advisory board for the International Flavors & Fragrances (IFF). Caroline Amand, Beatrice Bois De Fer, and Robert Lange are currently Sanofi employees and may hold shares and/or stock options in the company.

Figures

Fig. 1
Fig. 1
Patient disposition. aICD-10 codes related to constipation were K59.0, K59.9, or R19.4. bICD-10 codes related to secondary constipation or laxative abuse were K90.0, K51.x, K58.x, and F55.2. ICD international classification of diseases
Fig. 2
Fig. 2
Proportion of patients with dose change during the follow-up period in the long-term cohort
See this image and copyright information in PMC

References

    1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(9):1582–1591. doi: 10.1038/ajg.2011.164. - DOI - PubMed
    1. Corsetti M, Landes S, Lange R. Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation. Neurogastroenterol Motil. 2021;33(10):e14123. doi: 10.1111/nmo.14123. - DOI - PMC - PubMed
    1. Eoff JC. Optimal treatment of chronic constipation in managed care: review and roundtable discussion. J Manag Care Pharm. 2008;14(9 Suppl A):1-15. 10.18553/jmcp.2008.14.S8-A.1. - PMC - PubMed
    1. Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD, et al. Chronic constipation. Nat Rev Dis Primers. 2017;3:17095. doi: 10.1038/nrdp.2017.95. - DOI - PubMed
    1. Tack J, Muller-Lissner S, Stanghellini V, Boeckxstaens G, Kamm MA, Simren M, et al. Diagnosis and treatment of chronic constipation—a European perspective. Neurogastroenterol Motil. 2011;23(8):697–710. doi: 10.1111/j.1365-2982.2011.01709.x. - DOI - PMC - PubMed

LinkOut - more resources